We are Nα,Nε-Di-Boc-L-lysine Dicyclohexylammonium Salt CAS:15098-69-8 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name:Nα,Nε-Di-Boc-L-lysine Dicyclohexylammonium Salt
Molecular Weight: 527.73700
Nα,Nε-Bis(tert-butoxycarbonyl)-L-lysine Dicyclohexylammonium Salt
Physical and Chemical Properties:
Boiling point: 672.6ºC at 760 mmHg
Melting point: /
Flash point: 360.6ºC
Refractive index: /
Appearance: White powder
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at −20°C.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Related News: In terms of business, the industrial business increased by 7.97% year-on-year, while the revenue from the trading business shrank to a certain extent. The growth rate of industrial business was significantly slower than 24% in the first half of the year, showing that the growth rate of industrial business was lower in the third quarter, which was also the main reason for the decline in the company’s operating income in the third quarter. The company’s industrial business is mainly pesticide intermediates, accounting for about 85%. The scale of the pesticide intermediate business is large and the base is high, which is putting pressure on growth.3-Fluorobenzotrifluoride But the ban from Italy remains, Joseph Wu, Taiwan’s foreign minister, said on Sunday.picolinic acid New Zealand citizens and permanent residents and their immediate family members will still be able to enter — but must self-isolate for 14 days after arriving back into the country.1-diphenylphosphoryloxy-2,3,4,5,6-pentafluorobenzene CAS:138687-69-1 A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.